Larazotide
Larazotide is a research peptide in the Tight Junction Regulator class. Larazotide is a synthetic peptide antagonist of zonulin, the endogenous regulator of intestinal tight junctions. By blocking zonulin-mediated tight junction disassembly it is intended to reduce paracellular permeability, limiting passage of gliadin peptides across the epithelium and the downstream immune activation.
For research use only.
Key Facts
- CAS
- 258818-34-7
- Molecular Weight (MW)
- 725.8 g/mol
- Half-life
- —
- FDA status
- Investigational New Drug (IND)
- Administration Route
- oral
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Orally administered octapeptide investigated as an adjunct to a gluten-free diet in coeliac disease. It acts locally in the intestinal lumen. Not FDA-approved.
Peptide Library's Larazotide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- oral
- Reconstitution Guide
- —
Sequence & molecular data
| Amino acid sequence | Gly-Gly-Val-Leu-Val-Gln-Pro-Gly |
|---|---|
| Molecular formula | C32H55N9O10 |
| Molecular weight | 725.8 g/mol |
| CAS number | 258818-34-7 |
| PubChem CID | 9810532 |
| FDA UNII | ZN3R5560ZV |
| ChEMBL | CHEMBL2105646 |
| DrugBank | DB05645 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Larazotide is a synthetic peptide antagonist of zonulin, the endogenous regulator of intestinal tight junctions. By blocking zonulin-mediated tight junction disassembly it is intended to reduce paracellular permeability, limiting passage of gliadin peptides across the epithelium and the downstream immune activation. Because it is not meaningfully absorbed, its activity is confined to the gut lumen.
Studies
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide
- Celiac disease: Hope for new treatments beyond a gluten-free diet
- Larazotide acetate: a pharmacological peptide approach to tight junction regulation
- The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
- Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model
Regulatory & research status
Larazotide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Research status | Investigational; clinical development reported |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Larazotide: frequently asked questions
What is Larazotide?
Orally administered octapeptide investigated as an adjunct to a gluten-free diet in coeliac disease. It acts locally in the intestinal lumen. Not FDA-approved.
How does Larazotide work?
Larazotide is a synthetic peptide antagonist of zonulin, the endogenous regulator of intestinal tight junctions. By blocking zonulin-mediated tight junction disassembly it is intended to reduce paracellular permeability, limiting passage of gliadin peptides across the epithelium and the downstream immune activation.
Is Larazotide FDA approved?
No. Larazotide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the amino acid sequence of Larazotide?
Larazotide has the sequence Gly-Gly-Val-Leu-Val-Gln-Pro-Gly, giving a chain of 8 amino acids. Its molecular formula is C32H55N9O10.
What peptides are similar to Larazotide?
Compounds most often compared with Larazotide include Teduglutide, Linaclotide, Plecanatide and Secretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide — Sci Transl Med, 2025External reference
- Celiac disease: Hope for new treatments beyond a gluten-free diet — Clin Nutr, 2024External reference
- Larazotide acetate: a pharmacological peptide approach to tight junction regulation — Am J Physiol Gastrointest Liver Physiol, 2021External reference
- The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases — Curr Med Chem, 2021External reference
- Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model — Pediatr Neonatol, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Larazotide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Larazotide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →